newsfilter
← Latest News
GlobeNewswire·

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pacibekitug